Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males

International Journal of Urology

Volumn 14, Issue 10, 2007, Pages 930-934

  Kinoshita, Hidefumi ^a   Kamoto, Toshiyuki ^b   Nishiyama, Hiroyuki ^b   Nakamura, Eijiro ^b   Matsuda, Tadashi ^a   Ogawa, Osamu ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Biochemical progression; Prostate cancer; Prostate specific antigen nadir; Ultra sensitive prostate specific antigen

Indexed keywords

NADIR PROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL PARAMETERS; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; IMMUNOASSAY; JAPAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN DETERMINATION; RETROSPECTIVE STUDY;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 34548761992     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01858.x     Document Type: Article

References (25)

1. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 2002 167 : 528 34.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001 28 : 555 65.
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J. Urol. 2004 172 : 910 14.
4. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognostic ator of outcome following salvage radiotherapy. J. Urol. 2004 172 : 2244 8.
5. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 291 : 1325 32.
6. Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J. Urol. 2005 174 : 1282 6.
7. Terai A, Matsui Y, Yoshimura K, Arai Y, Dodo Y. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int. 2005 96 : 1009 13.
8. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997 50 : 573 9.
9. Arai Y, Okubo K, Aoki Y, Maekawa S, Okada T, Maeda H. Ultrasensitive assay of prostate-specific antigen for early detection of residual cancer after radical prostatectomy. Int. J. Urol. 1998 5 : 550 5.
10. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin. Chem. 1995 41 : 430 4.
11. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J. Urol. 1999 161 : 1206 11.
12. Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J. Urol. 2005 173 : 777 80.
13. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001 165 : 119 25.
14. Freedland SJ, Aronson WJ, Terris MK et al. The SEARCH Database Study Group. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J. Urol. 2003 169 : 2136 41.
15. Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology 2002 60 : 1034 9.
16. Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin. Chem. 1996 42 : 849 52.
17. Pu YS, Fujimoto H, Kakizoe T, Myers R. The 18th international symposium. Controversies in prostate cancer diagnosis and treatment. Jpn. J. Clin. Oncol. 2005 35 : 680 9.
18. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 2001 165 : 1146 51.
19. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 2003 17 : 1872 6.
20. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003 61 : 365 9.
21. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999 281 : 1395 00.
22. Shinghal R, Yemoto C, McNeal JE, Brooks JD. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. Urology 2003 6 : 380 5.
23. Walsh PC. Re: ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J. Urol. 2005 174 : 1501.
24. Bolla M, van Poppel H, Collette L et al. European Organization for Research and Treatment of Cancer: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005 366 : 572 8.
25. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993 71 : 3582 93.